<DOC>
	<DOCNO>NCT02205528</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial investigate efficacy , safety , tolerability once-daily subcutaneous ( SC ) injections NNC0090-2746 12 week , adjunct metformin , participant T2D .</brief_summary>
	<brief_title>A Study Once-Daily NNC0090-2746 Participants With Type 2 Diabetes Inadequately Controlled With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Participants age 18 70 year , inclusive Active diagnosis T2D great equal ( &gt; /= ) 3 month For female childbearing potential male female partner childbearing potential , agreement use highly effective contraceptive measure Treated stable dose metformin least 8 week prior randomization , expect remain stable dose throughout study participation Hemoglobin A1c ( HbA1c ) &gt; /= 7.2 % less equal ( &lt; /= ) 10.5 % Fasting plasma glucose ( FPG ) less ( &lt; ) 250 milligram per deciliter ( mg/dL ) Cpeptide great ( &gt; ) 1.5 nanogram per milliliter ( ng/mL ) Body mass index ( BMI ) &gt; /= 27 kilogram per metersquared ( kg/m^2 ) &lt; /= 44 kg/m^2 Stable weight ( +/ 5 % ) within 12 week prior Screening Willing able maintain exist diet exercise habit throughout study Capable perform SC selfinjections daily basis study Females pregnant lactate History type 1 diabetes ( T1D ) , diabetes result pancreatic injury , secondary form diabetes Cushing 's Syndrome acromegaly History acute metabolic complication diabetic ketoacidosis state hyperosmolar hyperglycemia History clinically significant diabetic complication diabetic proliferative retinopathy severe diabetic neuropathy ( require treatment antidepressant opioids ) History severe hypoglycemia within 6 month prior Screening History chronic gastrointestinal ( GI ) condition could impede gastric empty potentially affect interpretation study data History weight loss surgery weight loss procedure involve GI tract , gastric bypass , gastric stapling , gastric band History eat disorder ( e.g. , bulimia , anorexia ) History malignancy ( except treat basal squamous cell skin cancer ) within 5 year prior Screening Personal family history medullary thyroid carcinoma History multiple endocrine neoplasia syndrome type 2 History chronic acute pancreatitis hemochromatosis History significant cardiovascular disease ( congestive heart failure New York Heart Association Class II IV , myocardial infarction within previous 6 month , coronary disease , uncontrolled hypertension ) History clinically significant renal liver disease History hypersensitivity previous intolerance incretin glucagon analogue Elevations lipase amylase level Screening &gt; 1.5 time upper limit normal ( ULN ) consider clinically significant investigator Positive human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAG ) , hepatitis C antibody test Screening Receipt investigational drug within 30 day 5 halflives , whichever longer , prior Screening , active enrollment another investigational medication device study Any condition , disorder , abnormal laboratory test finding screen , judgment investigator , would interfere participant 's ability comply study requirement , would require administration treatment study could potentially affect interpretation study data , would place participant unacceptable risk his/her participation study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>